AI-driven biotech unicorn company Owkin has expanded its operations in Germany, Austria, and Switzerland, following partnerships with nine leading healthcare institutions. This collaboration is aimed to enhance AI-driven precision drug discovery and development.
Under the collaboration, Owkin will gather and analyze medical data from these hospitals to improve patient outcomes in prostate cancer, muscle-invasive bladder cancer, and cardiovascular disease. This will enable novel biomarker discovery, anticipate treatment responses, and develop more effective individualized therapies. These partnerships also will help to strengthen Owkin's MOSAIC network, a global initiative aiming to build the world's largest spatial omics dataset in oncology.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.